Keywords
SGLT2 Inhibitors
Benefits
How to Cite
Abstract
This article aims to discuss the benefits and clinical considerations of the use of SGLT2 inhibitors in the treatment of Chronic Kidney Disease, using the PubMed database with the terms "Chronic Kidney Disease", "SGLT2 Inhibitors", "Benefits". In summary, the evidence presented throughout this article reinforces the promising role of SGLT2 inhibitors in the treatment of Chronic Kidney Disease. The results demonstrated significant benefits in preserving renal function, in glycemic control and in improving the quality of life of patients. In addition, the reduction in the progression of CKD and the decrease in the incidence of renal adverse events highlight the importance of this class of drugs as a valuable therapeutic option. However, it is crucial that healthcare professionals are aware of the safety considerations associated with the use of SGLT2 inhibitors. Careful monitoring of patients, especially those with risk factors, is essential to maximize benefits and minimize potential side effects. Therefore, the integration of SGLT2 inhibitors into clinical practice must be carried out on an individual basis, considering the specific needs of each patient and always seeking a comprehensive and multidisciplinary approach in the management of Chronic Kidney Disease.
References
BOTELHO, Louise Lira Roedel; DE ALMEIDA CUNHA, Cristiano Castro; MACEDO, Marcelo. O método da revisão integrativa nos estudos organizacionais. Gestão e sociedade, v. 5, n. 11, p. 121-136, 2011.
CHERTOW, Glenn M. et al. Effects of dapagliflozin in stage 4 chronic kidney disease. Journal of the American Society of Nephrology, v. 32, n. 9, p. 2352-2361, 2021.
DE SÁ ARAÚJO, Cristiene Neta et al. Efeito dos inibidores do co-transportador sódio-glicose tipo 2 sobre o desfecho renal: Uma revisão integrativa. Research, Society and Development, v. 12, n. 3, p. e29512340810-e29512340810, 2023.
FERREIRA, Fernando José Gomes. O uso dos inibidores SGLT2 na melhora do desfecho clínico em pacientes com insuficência cardíaca e doença renal crônica: uma revisão sistemática. Repositório Institucional do Unifip, v. 7, n. 1, 2022.
JOHNSTON, Rhona et al. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment, v. 21, n. 2, p. 1-218, 2017.
KELLY, Michael S. et al. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgraduate medicine, v. 131, n. 1, p. 31-42, 2019.
MARINHO, Ana Wanda Guerra Barreto et al. Prevalência de doença renal crônica em adultos no Brasil: revisão sistemática da literatura. Cadernos Saúde Coletiva, v. 25, p. 379-388, 2017.
MENDE, Christian W. Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape. Advances in therapy, v. 39, n. 1, p. 148-164, 2022.
ŞAHIN, Serdar et al. Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleepquality, quality of life, and anxiety levels in people with type 2 diabetes mellitus?. Turkish Journal of Medical Sciences, v. 51, n. 2, p. 735-742, 2021.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Victoria Ribeiro, Maria Alice Cruz Simões , Thanisy Freitas Ribeiro, Diogo Mariano Hildefonso , Alessandro Menezes Saldanha Feijó , Guilherme Batista Remígio, Paula Vieira Villar, Henrique Bandoli de Amorim, Marina Lima Gaspar Carvalho da Silva , Ana Luiza Andrade Fantoni, Yasmin Naray Gasparetto da Cunha, Lidia Faria Teixeira